Swiss Biotech Day once again proved its standing as a central European hub for innovation, bringing together over 3,500 registrants from 58 countries, 150+ exhibitors, 31 international delegations, and more than 60 panel and roundtable discussions; a testament to the event’s remarkable scale and reach.
For Accelsiors, attending Swiss Biotech Day was an opportunity to strengthen our global network, engage with key stakeholders across the clinical development landscape, and present our services and latest company developments. As a Swiss CRO, events like this are close to our heart and this year’s edition did not disappoint.
A Landscape in Motion
One of the most striking observations was the noticeable growth in the number of service providers compared to previous years, reflecting a clear industry shift toward more tailored, patient-centric, and cost-efficient approaches to clinical development. Equally striking was how deeply artificial intelligence has embedded itself into the clinical trials ecosystem, from study design and patient recruitment all the way through to data analysis and monitoring. AI is no longer a future prospect; it is an active driver of efficiency today.
We also noted a rising demand for clinical trials in the medical devices space, mirroring the rapid innovation and regulatory momentum within that segment. Growing interest in Asian and Latin American markets added another dimension to the conversations, signaling that geography continues to reshape where and how trials are being conducted.
Meaningful Connections, Promising Follow-Ups
Over the course of the event, our team held approximately 15 to 20 meetings, the majority with early-stage biotech companies. These organizations brought forward truly inspiring ideas and ambitious development plans. Many are actively seeking funding, strategic partnerships, and operational support and it is precisely here that Accelsiors can make a meaningful difference, offering the flexibility and precision that emerging companies need to move their programs forward.
The conversations we had at Swiss Biotech Day have already translated into concrete next steps, with several online follow-up meetings scheduled with broader members of our team. We look forward to building on these connections and turning initial discussions into lasting collaborations.
A Positive Trajectory
Perhaps the most encouraging signal from this year’s event was a sense of renewal across the industry. The headwinds that characterized previous years appear to be fading, replaced by renewed engagement, increased activity, and genuine interest in partnership. Swiss Biotech Day captured this momentum beautifully and Accelsiors is proud to be part of a community that continues to push the boundaries of what is possible in biotechnology and clinical development.
On behalf of our colleagues, Marco Villa, Head of Business Development and Acceleroute, and Sunčica Bakić, MBA, Business Development Manager, who attended the event, thank you for all the meaningful connections and opportunities for collaboration. ‘Till the next year!
